Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

NCT02751710 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

369

Enrollment

OTHER

Sponsor class

Conditions

Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
Stage IIb Breast Cancer (T3N0)

Interventions

OTHER: Whole-body FDG PET-CT alone

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]